CymaBay: Positive Phase 3 Data And Competitive Advantage Established

Terry Chrisomalis
Investing Group Leader

Summary

  • Positive results achieved in phase 3 RESPONSE study, which used seladelpar for the treatment of patients with primary biliary cholangitis.
  • Positive results of the phase 3 RESPONSE study leads to additional data at an upcoming medical meeting and possibly several regulatory submissions of seladelpar for primary biliary cholangitis.
  • The global primary biliary cholangitis market is expected to reach $1.4 billion by 2032.
  • The Phase 2a proof-of-pharmacology study data using MBX-2982 to prevent hypoglycemia in Type 1 Diabetes patients, expected before the end of 2023.
  • Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More »

Medical Research Laboratory: Portrait of a Beautiful Female Scientist in Goggles Using Micro Pipette for Test Analysis. Advanced Scientific Lab for Medicine, Biotechnology, Microbiology Development

gorodenkoff

CymaBay Therapeutics (CBAY) had made great progress in advancing the use of its drug seladelpar, because it was able to achieve a successful outcome for its phase 3 study known as RESPONSE, which treated patients with primary biliary

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33.50% discount price of $399 per year.

This article was written by

Terry Chrisomalis
13.46K Followers

Terry Chrisomalis is a private investor in the Biotech sector with years of experience utilizing his Applied Science background to generate long term value from Healthcare.

He is the author of the investing group Biotech Analysis Central which contains a library of 600+ Biotech investing articles, a model portfolio of 10+ small and mid-cap stocks with deep analysis for each, live chat, and a range of analysis and news reports to help Healthcare investors make informed decisions.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

More on CBAY

Trending Analysis

Trending News